Profile: Lannett Company Inc (LCI.A)
13 Dec 2017
Lannett Company, Inc., incorporated on December 3, 1991, develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.
Levothyroxine Sodium Tablets
The Company's Levothyroxine Sodium tablets are used for the treatment of thyroid deficiency by patients of various ages and demographic backgrounds. As of June 30, 2016, it is produced and marketed in 12 potencies. Levothyroxine Sodium tablets are used by patients of various ages and demographic backgrounds for the treatment of thyroid deficiency.
The Company's Digoxin tablets are used to treat congestive heart failure in patients of various ages and demographics. As of June 30, 2016, it is produced and marketed with two different potencies.
The Company's Acetazolamide tablets are used for the treatment of glaucoma. The product is a carbonic anhydrase inhibitor that reduces fluid pressure in the eyeball. It also increases the removal of water from the body by the kidneys and may block certain nerve discharges that may contribute to seizures.
As of June 30, 2016, the Company distributed three products containing Butalbital. Butalbital products, which were orally administered in capsule or tablet dosage forms, are prescribed to treat migraines and tension headaches caused by contractions of the muscles in the neck and shoulder area. The drug is prescribed primarily for adults of various demographics.
As of June 30, 2016, the Company's Ursodiol Capsules were produced and marketed in 300 milligram (mg) capsules. Ursodiol capsules are used for the treatment of gallstones.
Omeprazole is a proton pump inhibitor that decreases the amount of acid produced in the stomach. The product is a generic version of the branded drug, Prilosec. It is indicated for heartburn or irritation of the esophagus caused by gastroesophageal reflux disease. The Company's subsidiary, Kremers Urban Pharmaceuticals Inc. (KUPI), produced Omeprazole DR Capsules in 10 mg, 20 mg and 40 mg dosages as of June 30, 2016.
Methylphendiate Hydrochloride ER
Methylphenidate ER is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children approximately six years of age and older, adolescents and adults up to the age of 65. The product is a generic version of the branded drug Concerta.
Pain Management Products
The Company's Cocaine Topical Solution (C-Topical) is produced and marketed under a preliminary new drug application (PIND) in two different strengths and two different size containers as of June 30, 2016. C-Topical is utilized primarily for the anesthetization of the patient during ear, nose or throat surgery and sinoplasty. The Company has completed a Phase III clinical trial and its Clinical Research Organization (CRO) is assembling the data for its New Drug Application (NDA) for C-Topical and continues to market the product utilizing a group of brand representatives in market locations throughout the United States.
The Company's Morphine Sulfate Oral Solution was produced and marketed in three different size containers as of June 30, 2016. The Company manufactures this product at Cody Labs and is finishing the manufacturing methods and capabilities to make the API. This drug is prescribed primarily for the management of pain in adults. Other products in the pain management franchise include Hydromorphone HCl tablets and Codeine Sulfate tablets.
The Company competes with Taro Pharmaceutical Industries, Mallinckrodt, Mikart, Qualitest, Watson, West-Ward, Actavis, Breckenridge, Mylan, Impax, Sun, Concordia, AbbVie, Pfizer, Sandoz, Janssen, Dr. Reddy's, Zydus and Epic.
Lannett Company Inc
9000 State Rd
PHILADELPHIA PA 19136-1615
Company Web Links
- BRIEF-Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution
- BRIEF-Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL
- BRIEF-Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance
- BRIEF-Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing
- BRIEF-Lannett Co calls price fixing allegations about a single product named in complaint that co sells "meritless"